Israel's strikes on Iran could take oil prices above $80. This has implications for the global economy, markets and policy ...

The net profit margin will improve from 3.4% to 3.7%, while operating profits are forecast to rise to $66.0 bn from $61.9bnn ...

Rather, the interesting thing is that after years of underperformance European stocks are ruling the 2025 global equity roost.  And, in our view, that is a position they are unlikely to soon ...

"So the risk factors or causes of obesity are inclusive of an unhealthy diet, a sedentary lifestyle, genetics plays a role, lack of sleep. And there are some underlying conditions that predispose ...

The company's geopolitical headwinds have eased ... The stock is deserving of a Buy, considering these favorable factors. The group's latest quarterly financials released last week were a positive ...

JPMorgan Chase & Co., the largest bank in the United States, has published a geopolitical analysis on Russia’s war ... JPMorgan attributes this projected outcome to a confluence of factors: Europe ...

Ever since the concept of one-euro Italian homes emerged a few years ago, there’s been a recognized pattern to these highly popular sell-offs of crumbling properties in charming but depopulated ...

The Euro remains under pressure after Q1 GDP ... The Japanese Yen draws support from broader macroeconomic and geopolitical factors. Persistent global trade uncertainties pressured the US Dollar ...

The euro fell to $1.1107 from $1.1209 ... Apart from trade talks and other geopolitical factors, the flow of earnings reports for the start of the year from companies is slowing but still moving ...

Several experts set to speak at the second vertical pv magazine is organizing as part of Net Zero said geopolitical factors – particularly the availability of critical raw materials such as ...

The global factors will continue to have a higher impact ... are resistance at $3,450 and support at $3,200. On Tuesday, the euro (EUR/USD) rose broadly by 0.47% after Germany’s parliament ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ...